Presentation is loading. Please wait.

Presentation is loading. Please wait.

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies by Jutta Deckert, Peter U. Park,

Published byRalf Freeman Modified over 8 years ago

Similar presentations

Presentation on theme: "A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies by Jutta Deckert, Peter U. Park,"— Presentation transcript:

1 A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies by Jutta Deckert, Peter U. Park, Sharon Chicklas, Yong Yi, Min Li, Katharine C. Lai, Michele F. Mayo, Christina N. Carrigan, Hans K. Erickson, Jan Pinkas, Robert J. Lutz, Thomas Chittenden, and John M. Lambert Blood Volume 122(20):3500-3510 November 14, 2013 ©2013 by American Society of Hematology

2 Examples of CD37 staining on human lymphoma samples. Jutta Deckert et al. Blood 2013;122:3500-3510 ©2013 by American Society of Hematology

3 In vitro activity of K7153A antibody on lymphoma cell lines. Jutta Deckert et al. Blood 2013;122:3500-3510 ©2013 by American Society of Hematology

4 IMGN529 structure and in vitro activity. Jutta Deckert et al. Blood 2013;122:3500-3510 ©2013 by American Society of Hematology

5 IMGN529 has specific cytotoxicity against CD37+ lymphoma cell lines. Jutta Deckert et al. Blood 2013;122:3500-3510 ©2013 by American Society of Hematology

6 IMGN529 conjugate induces G2/M cell cycle arrest. Jutta Deckert et al. Blood 2013;122:3500-3510 ©2013 by American Society of Hematology

7 In vivo efficacy of IMGN529 in tumor xenograft models. Jutta Deckert et al. Blood 2013;122:3500-3510 ©2013 by American Society of Hematology

8 IMGN529 specifically depletes normal and malignant human B cells. Jutta Deckert et al. Blood 2013;122:3500-3510 ©2013 by American Society of Hematology

Download ppt "A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies by Jutta Deckert, Peter U. Park,"

Similar presentations

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.
Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):3102-3111.

Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):
The β2 integrin–kindlin-3 interaction is essential for T-cell homing but dispensable for T-cell activation in vivo by Vicky Louise Morrison, Matthew MacPherson,

The β2 integrin–kindlin-3 interaction is essential for T-cell homing but dispensable for T-cell activation in vivo by Vicky Louise Morrison, Matthew MacPherson,
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.
Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13):4793-4807 December 15, 2008 ©2008 by American Society of Hematology.

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,

Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated.

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated.
Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes.

Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes.
Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry by Po-Lin Chiu, George M. Bou-Assaf,

Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry by Po-Lin Chiu, George M. Bou-Assaf,
CD8 + T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia by Li Ma, Elisa Simpson,

CD8 + T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia by Li Ma, Elisa Simpson,
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c by Robert M. Cohen, Robert S. Franco, Paramjit K. Khera,

Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c by Robert M. Cohen, Robert S. Franco, Paramjit K. Khera,
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma by Thomas E. Witzig,

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma by Thomas E. Witzig,
Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell–, and not B cell–, dependent antilymphoma immunity by Hong Qin, Soung-chul.

Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell–, and not B cell–, dependent antilymphoma immunity by Hong Qin, Soung-chul.
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
Strategies for the Identification of T Cell–Recognized Tumor Antigens in Hematological Malignancies for Improved Graft-versus-Tumor Responses after Allogeneic Blood.

Strategies for the Identification of T Cell–Recognized Tumor Antigens in Hematological Malignancies for Improved Graft-versus-Tumor Responses after Allogeneic Blood.
The beauty of TLR agonists for CTCL

The beauty of TLR agonists for CTCL

Similar presentations

Ads by Google